HR Execs on the Move

Revance

www.revance.com

 
Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.revance.com
  • 7555 Gateway Boulevard
    Newark, CA USA 94560
  • Phone: 510.742.3400

Executives

Name Title Contact Details
Jennifer Parker
Director of Professional Marketing Profile
Amie Krause
Chief People Officer Profile
Liz Craig
Senior Director, Human Resources Profile
Kelly Trendell Smith
Director Talent Acquisition Profile

Similar Companies

NeuroPace

NeuroPace is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Armata Pharmaceuticals

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.

Human Genome Sciences

Human Genome Sciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.

Chiral Quest

Chiral Quest is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.